文献速递分子诊断临床微生物质量管理与危急值

Onclarity HPV检测迁移至COR高通量仪器后的临床验证

Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program.
PubMed 文献 · Am J Clin Pathol · 2022-01-01

该研究在丹麦宫颈癌筛查项目中,使用SurePath筛查样本对Onclarity HPV检测在COR高通量仪器上的性能进行临床验证。该仪器每日手动操作时间58分钟,适合用于HPV初筛。

要点

  • 实验室内重复性98.3%(κ=0.96),室间一致性98.5%(κ=0.96)。

核心结论

  • Onclarity-COR在灵敏度、特异性和实验室重复性方面符合国际验证标准。

研究设计与样本

  • 使用BD SurePath采集的30岁及以上女性筛查样本进行验证。
  • 以GP5+/6+酶免疫分析(GP-EIA)为 comparator,评估122例CIN2+样本的临床灵敏度。
  • 使用887例两次细胞学正常样本评估特异性,525例样本评估重复性,并进行时间动作研究。

主要发现

  • 实验室内重复性为98.3%(κ=0.96),室间一致性为98.5%(κ=0.96)。
  • COR仪器每日手动操作时间为58分钟,每8小时班次中离机时间为7小时2分钟。

关键数值与推荐

  • 实验室内重复性98.3%(κ=0.96),室间一致性98.5%(κ=0.96)。

临床怎么用

  • Onclarity-COR的高通量特性和扩展基因分型能力使其适合用于HPV初筛宫颈癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study presents the clinical assessment of the Onclarity HPV Assay (Becton Dickinson) on the novel COR high-throughput instrument (Becton Dickinson) using the international guidelines in a routine setting. METHODS: Screening samples collected in BD SurePath from women aged 30 years and older were used in this validation. Noninferiority of the Onclarity HPV Assay on the COR instrument (Onclarity-COR) was assessed with the comparator assay glycoprotein 5-positive (GP5+)/6+ enzyme immunoassay (GP-EIA) for clinical sensitivity on 122 cervical intraepithelial neoplasia 2 and greater samples. Specificity was assessed using 887 samples with twice-normal cytology. Inter- and intralaboratory reproducibility analysis was assessed using 525 samples. Finally, a time-and-motion study was performed to evaluate COR instrument performance characteristics. RESULTS: The Onclarity-COR was noninferior to the GP-EIA for both sensitivity (P = .0016) and specificity (P < .0001). The intralaboratory reproducibility was 98.3% (κ = 0.96), and interlaboratory agreement was 98.5 % (κ = 0.96). The daily hands-on time for the COR instrument was 58 minutes, and walk-away time was 7 hours, 2 minutes per 8-hour day shift. CONCLUSIONS: The Onclarity-COR instrument fulfills international validation criteria on sensitivity, specificity, and laboratory reproducibility. The Onclarity assay's extended genotyping capability, together with its high-throughput characteristics, makes the COR instrument an excellent candidate for use in human papillomavirus primary cervical cancer screening.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Ejegod DM, Pedersen H, Pedersen BT, et al. Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program. Am J Clin Pathol. 2022. PMID: 34546350. doi:10.1093/ajcp/aqab138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。